Inhibition of vascular angiotensin-coverting enzyme by telmisartan via the peroxisome proliferator-activated receptor γ agonistic property in rats

Hypertension Research

Volumn 30, Issue 12, 2007, Pages 1231-1237

  Takai, Shinji ^a   Jin, Denan ^a   Kimura, Maki ^a   Kirimura, Kazuyoshi ^b   Sakonjo, Hiroshi ^b   Tanaka, Kazuhiko ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b Shiga Research Center   (Japan)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme; Oxidative stress; Peroxisome proliferator activated receptor ; Vasorelaxation

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN 1 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SODIUM CHLORIDE; TELMISARTAN; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBUNIT; HYPERTENSION; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VASODILATATION; WISTAR KYOTO RAT;

ACETYLCHOLINE; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CAROTID ARTERIES; DISEASE MODELS, ANIMAL; HYPERTENSION; MALE; NADPH OXIDASE; PEPTIDYL-DIPEPTIDASE A; PPAR GAMMA; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RENIN; TETRAZOLES; VALINE; VASODILATION; VASODILATOR AGENTS;

EID: 38749117951     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.1231     Document Type: Article

References (28)

1. Benson SC, Pershadsingh HA, Ho CI, et al: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004; 43: 993-1002.
2. Schupp M, Janke J, Clasen R, Unger T, Kintscher U: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 2004; 109: 2054-2057.
3. Picard F, Auwerx J: PPARγ and glucose homeostasis. Annu Rev Nutr 2002; 22: 167-197.
4. Toba H, Miki S, Shimizu T, et al: The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta. Eur J Pharmacol 2006; 549: 124-132.
5. Kanemitsu H, Takai S, Tsuneyoshi H, et al: Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats. Hypertens Res 2006; 29: 57-64.
6. Kirimura K, Takai S, Jin D, et al: Role of chymase-dependent angiotensin II formation in regulating blood pressure in spontaneously hypertensive rats. Hypertens Res 2005; 28: 457-464.
7. Takai S, Kirimura K, Jin D, et al: Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res 2005; 28: 593-600.
8. Tanaka H, Takai S, Jin D, et al: Inhibition of matrix metalloproteinase-9 activity by trandolapril after middle cerebral artery occlusion in rats. Hypertens Res 2007; 30: 469-475.
9. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, β, and -γ in the adult rat. Endocrinology 1996; 137: 354-366.
10. Fernandez-Alfonso MS, Kreutz R, Zeh K, Liu Y, Ganten D, Paul M: Differential regulation of vascular angiotensin I-converting enzyme in hypertension. Hypertension 1994; 24: 280-286.
11. Takai S, Jin D, Sakaguchi M, Miyazaki M: Significant target organs for hypertension and cardiac hypertrophy by angiotensin-converting enzyme inhibitors. Hypertens Res 2004; 27: 213-219.
12. Verma S, Bhanot S, McNeill JH: Direct vasodepressor effects of pioglitazone in spontaneously hypertensive rats. Pharmacology 1998; 56: 7-16.
13. Grinsell JW, Lardinois CK, Swislocki A, et al: Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat. Am J Hypertens 2000; 13: 370-375.
14. Wakino S, Hayashi K, Tatematsu S, et al: Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res 2005; 28: 255-262.
15. Campia U, Matuskey LA, Panza JA: Peroxisome proliferator-activated receptor-γ activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 2006; 113: 867-875.
16. phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997; 80: 45-51.
17. Ulker S, McMaster D, McKeown PP, Bayraktutan U: Impaired activities of antioxidant enzymes elicit endothelial dysfuncfion in spontaneous hypertensive rats despite enhanced vascular nitric oxide generation. Cardiovasc Res 2003; 59: 488-500.
18. Hamilton CA, Brosnan MJ, Al-Benna S, Berg G, Dominiczak AF: NAD(P)H oxidase inhibition improves endothelial function in rat and human blood vessels. Hypertension 2002; 40: 755-762.
19. 2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 2001; 50: 3-11.
20. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK: Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002; 91: 406-413.
21. Takai S, Sakonjo H, Miyazaki M: Beneficial effect of trandolapril on the lifespan of a severe hypertensive model. Hypertens Res 2001; 24: 559-564.
22. Morishita R, Higaki J, Nakamura F, et al: Regression of hypertension-induced vascular hypertrophy by an ACE inhibitor and calcium antagonist in the spontaneously hypertensive rat. Blood Press 1992; 3 (Suppl): 41-47.
23. Mizuno K, Niimura S, Katoh K, Fukuchi S: TCV-116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue renin-angiotensin system in spontaneously hypertensive rats. Life Sci 1994; 54: 1987-1994.
24. Diep QN, Amiri F, Benkirane K, Paradis P, Schiffrin EL: Long-term effects of the PPAR γ activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats. Can J Physiol Pharmacol 2004; 82: 976-985.
25. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW: Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006; 47: 1003-1009.
26. Mori Y, Itoh Y, Tajima N: Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens 2001; 20: 431-436.
27. Ishibashi M, Egashira. K, Hiasa K, et al: Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002; 40: 687-693.
28. Imayama I, Ichiki T, Inanaga K, et al: Telmisartan down-regulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor γ. Cardiovasc Res 2006; 72: 184-190.